Neurology
Clene Inc. Advances Toward FDA Approval for ALS Treatment, Highlighting Market Potential
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
Clene Inc. Advances Neurodegenerative Disease Treatment with FDA-Backed Biomarker Analysis
Clene Inc. is set to initiate neurofilament biomarker analyses for its drug CNM-Au8 in ALS patients, marking a significant step towards innovative treatments for neurodegenerative diseases.
ReAlta’s Pegtarazimod Demonstrates Potential in Reducing Brain Inflammation in Newborns with HIE
A preclinical study reveals pegtarazimod's ability to significantly reduce brain inflammation in newborns with hypoxic ischemic encephalopathy (HIE), offering hope for a new treatment approach.
Study Reveals Early Health Visits May Predict Multiple Sclerosis Decades Before Diagnosis
A recent study indicates that individuals later diagnosed with multiple sclerosis visit healthcare providers more frequently decades before their diagnosis, suggesting potential for earlier intervention.
Lorati's Nano-Emulsion Offers New Hope for Stroke Recovery
Lorati Co., Ltd. introduces a natural, mineral-based nano-emulsion therapy that promises a non-invasive solution for full recovery from both hemorrhagic and ischemic strokes, marking a significant advancement in stroke treatment.
Jupiter Neurosciences Advances in Treating Neuroinflammation and Aging with JOTROL™ and Nugevia™
Jupiter Neurosciences Inc. is making strides in treating central nervous system disorders and tapping into the longevity market with its innovative products JOTROL™ and Nugevia™, highlighting the potential to combat aging and neuroinflammation.
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D
Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.
Clene Inc. Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Clene Inc. progresses in its regulatory strategy for CNM-Au8, with FDA meetings set to discuss ALS and MS treatments, marking a significant step towards potential accelerated approval.
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025
Annovis Bio Inc. will present significant advancements in Alzheimer’s treatment at the Alzheimer’s Association International Conference 2025, highlighting the potential of its lead candidate, buntanetap.
NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC
NeuroSense Therapeutics' progress with Health Canada for its ALS drug PrimeC could accelerate approval and bolster a significant pharmaceutical partnership, highlighting a pivotal moment for ALS treatment and the biotech sector.
New Scanning Method Research Funded to Improve Brain Tumor Treatment
Researchers from NHS Grampian and the University of Aberdeen receive funding to explore a novel scanning method that could enhance the treatment of aggressive brain tumors, specifically glioblastomas.
Lexaria Bioscience Corp. Achieves Global Patent Milestone with 50 Patents
Lexaria Bioscience Corp. has reached a significant milestone with 50 patents granted worldwide, including new patents for epilepsy treatment and sublingual nicotine delivery, marking a pivotal moment in the company's strategy to expand its drug delivery platform.
Quantum BioPharma Ltd. Advances in Brain and Alcohol Health Research with Phase 2 Trial Approval
Quantum BioPharma Ltd. makes significant strides in its brain disorders and alcohol health pipeline, including Phase 2 trial approval for FSD202 and preparations for an IND filing for Lucid-MS, highlighting its commitment to addressing unmet medical needs.
Cure Alzheimer’s Fund Honors Breakthrough Research with Jeffrey L. Morby Prize
The Cure Alzheimer’s Fund has awarded the Jeffrey L. Morby Prize to researchers Andrew S. Yoo and Zhao Sun for their innovative study on modeling late-onset Alzheimer’s disease, marking a significant step forward in understanding and potentially treating the condition.
Quantum BioPharma Advances MS Research with Groundbreaking PET Imaging Study
Quantum BioPharma Ltd. has initiated a pioneering PET imaging study with Massachusetts General Hospital to track myelin integrity in multiple sclerosis patients, potentially revolutionizing treatment evaluation.
Study Reveals Accelerated Biological Aging in Children with Multiple Sclerosis
New research from UC San Diego indicates that children and adolescents with multiple sclerosis experience faster biological aging, highlighting the urgent need for targeted therapies.
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.
Neuroscientists Develop RADICAL: A Breakthrough Tool for Precise Neural Control
Researchers have engineered a novel chemogenetic tool called RADICAL that enables non-invasive, precise manipulation of brain activity using a synthetic chemical, offering significant potential for neuroscience research and therapeutic interventions.
Swedish Study Reveals Potential Neurological Connection Between Autism and Parkinson's Disease
A groundbreaking research from Karolinska Institutet suggests a significant biological link between autism spectrum disorder and Parkinson's disease, potentially opening new avenues for understanding neurodegenerative conditions.
Alzamend Neuro Advances Innovative Therapies for Mental Health Disorders
Alzamend Neuro is developing novel therapeutic approaches for challenging neurological and psychiatric conditions, including Alzheimer's, Bipolar Disorder, Major Depressive Disorder, and PTSD. The company's pioneering treatments aim to improve patient outcomes by addressing current treatment limitations.
Alzamend Neuro Launches Phase II Trial for Innovative Lithium-Based Alzheimer's Therapy
Alzamend Neuro has initiated a Phase II clinical trial for AL001, a novel lithium therapy targeting multiple neuropsychiatric conditions, with potential to improve brain drug delivery and reduce side effects.
Breakthrough Brain Tumor Test Promises Faster Diagnosis
A new diagnostic test for brain tumors could dramatically reduce the time needed for accurate diagnosis, potentially improving patient outcomes by enabling quicker treatment decisions.
New Research Illuminates Potential Link Between Epstein-Barr Virus and Multiple Sclerosis
Scientific research is uncovering a complex relationship between Epstein-Barr virus exposure and Multiple Sclerosis, highlighting the potential for deeper understanding of disease mechanisms and future treatment strategies.
Viral TikTok Video Highlights Simple Hand Motion Test for Potential Brain Tumor Detection
A social media trend reveals a 30-second hand test that could help individuals identify potential undiagnosed brain health issues, raising awareness about early symptom recognition.
Oragenics Receives Australian Approval for Phase II Concussion Trial
Biotechnology company Oragenics has secured regulatory approval to launch a Phase II clinical trial for ONP-002, a novel intranasal therapy targeting mild traumatic brain injury. The trial represents a potential advancement in treating concussions with a non-invasive approach.
CNS Pharmaceuticals Secures Orphan Drug Designation for Brain Cancer Treatment
CNS Pharmaceuticals has transferred Orphan Drug Designation for TPI 287, a promising microtubule-stabilizing drug targeting brain cancer and neurological conditions. The designation could provide significant market advantages and potential treatment options for patients with challenging neurological disorders.
Oragenics to Discuss Promising Concussion Treatment in Upcoming Webinar
Biotechnology company Oragenics will host a management webinar to highlight its lead intranasal therapy ONP-002, currently in Phase IIa trials for mild traumatic brain injury, potentially addressing an unmet medical need in concussion treatment.